全文获取类型
收费全文 | 26827篇 |
免费 | 2394篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 258篇 |
儿科学 | 924篇 |
妇产科学 | 794篇 |
基础医学 | 3447篇 |
口腔科学 | 561篇 |
临床医学 | 3624篇 |
内科学 | 4678篇 |
皮肤病学 | 287篇 |
神经病学 | 2376篇 |
特种医学 | 697篇 |
外国民族医学 | 1篇 |
外科学 | 3299篇 |
综合类 | 612篇 |
一般理论 | 44篇 |
预防医学 | 3648篇 |
眼科学 | 525篇 |
药学 | 1830篇 |
1篇 | |
中国医学 | 36篇 |
肿瘤学 | 1621篇 |
出版年
2023年 | 199篇 |
2022年 | 291篇 |
2021年 | 549篇 |
2020年 | 377篇 |
2019年 | 609篇 |
2018年 | 693篇 |
2017年 | 481篇 |
2016年 | 566篇 |
2015年 | 622篇 |
2014年 | 815篇 |
2013年 | 1159篇 |
2012年 | 1758篇 |
2011年 | 1787篇 |
2010年 | 947篇 |
2009年 | 842篇 |
2008年 | 1507篇 |
2007年 | 1589篇 |
2006年 | 1479篇 |
2005年 | 1438篇 |
2004年 | 1437篇 |
2003年 | 1341篇 |
2002年 | 1202篇 |
2001年 | 511篇 |
2000年 | 463篇 |
1999年 | 461篇 |
1998年 | 280篇 |
1997年 | 241篇 |
1996年 | 190篇 |
1995年 | 187篇 |
1994年 | 164篇 |
1993年 | 184篇 |
1992年 | 308篇 |
1991年 | 286篇 |
1990年 | 288篇 |
1989年 | 257篇 |
1988年 | 238篇 |
1987年 | 205篇 |
1986年 | 266篇 |
1985年 | 206篇 |
1984年 | 171篇 |
1983年 | 181篇 |
1982年 | 142篇 |
1981年 | 137篇 |
1980年 | 139篇 |
1979年 | 179篇 |
1978年 | 147篇 |
1977年 | 139篇 |
1975年 | 141篇 |
1974年 | 150篇 |
1973年 | 154篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
2.
James A. Akingbasote Alison J. Foster Ian Wilson Sunil Sarda Huw B. Jones J. Gerry Kenna 《Archives of toxicology》2016,90(4):853-862
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment. 相似文献
3.
4.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
5.
6.
7.
8.
9.
10.